Funder
Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais
Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
Associa??o de Combate ao C?ncer do Centro Oeste de Minas Gerais
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference39 articles.
1. INCA (Instituto Nacional do Câncer). Estimativa 2018. Incidência do Câncer no Brasil. INCA. 1nd ed. Rio de Janeiro, 2017.
2. Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 2016;160:393–410.
3. NCCN—National Comprehensive Cancer Network. Clinical practice guidelines in oncology. genetic/familial high-risk assessment: breast and ovarian (version 2.2017). 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed 15 Dec 2017.
4. Palmero EI, Schuler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008;261:21–5.
5. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007;245:96–102.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献